The information on this website is provided “as is” without any representations or warranties, express or implied. DanSharpIBD.org makes no representations or warranties in relation to the information on this website. You must not rely on the information on this website as an alternative to medical advice from your doctor or other professional healthcare provider. If you have any specific questions about any medical matter you should consult your doctor or other professional healthcare provider. If you think you may be suffering from any medical condition you should seek immediate medical attention. You should never delay seeking medical advice, disregard medical advice, or discontinue medical treatment because of information on this website. Nothing in this medical disclaimer will limit any of our liabilities in any way that is not permitted under applicable law, or exclude any of our liabilities that may not be excluded under applicable law.
Twitter
The delta of 33% for clinical remission by CDAI is pretty impressive, especially with a lot of bio-experienced patients. Larger than IFX in the bionaive era in ACCENT. https://twitter.com/mchiorean4/status/1524768083285405697
Upadacitinib (selective JAK1-inhibitor) achieved all clinical & endoscopic endpoints for maintenance in #CrohnsDisease in the phase 3 program. Number needed to treat of 3 for clinical and 4 for endoscopic endpoints. Great news for our #IBD patients https://news.abbvie.com/news/press-releases/upadacitinib-rinvoq-achieved-clinical-remission-and-endoscopic-response-at-one-year-in-phase-3-maintenance-study-in-patients-with-crohns-disease.htm?view_id=2421
